Alkem Laboratories Ltd.

Alkem Laboratories Ltd. is an Indian multinational pharmaceutical company founded in 1973. Headquartered in Mumbai, India, the company is publicly traded on the Bombay Stock Exchange (BSE: 539523) and the National Stock Exchange of India (NSE: ALKEM). Alkem is a large-scale enterprise, employing over 20,000 people and reporting revenue of approximately $1.62 billion for the trailing twelve months as of December 31, 2025.

Alkem Laboratories is an operating company that develops, manufactures, and markets a wide range of pharmaceutical products. Its portfolio includes branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals. The company has a strong presence in therapeutic areas such as anti-infectives, gastro-intestinal, pain management, and vitamins/minerals. Some of its well-known brands in India are Clavam, Pan, Pan-D, and Taxim-O. Alkem operates 21 manufacturing facilities, with 19 located in India and two in the United States.

As an operating company in the pharmaceutical sector, Alkem Laboratories is postured as a defendant in patent litigation. The provided data shows Alkem as a defendant in one U.S. patent case and as a plaintiff in none. This is typical for a generics manufacturer, which often faces litigation from brand-name drug companies when seeking to market generic versions of existing drugs. The single tracked case was filed in the U.S. District Court for the District of Delaware, a common venue for pharmaceutical patent disputes.

The tracked case is Veloxis Pharmaceuticals, Inc. v. Alkem Laboratories Ltd., filed on July 3, 2024. This type of litigation, known as an Abbreviated New Drug Application (ANDA) case, is common under the Hatch-Waxman Act, where a generic drug manufacturer like Alkem challenges the patents of a branded drug, in this instance Envarsus XR® (an extended-release tablet), in order to bring a more affordable version to market.